BioBusiness Update | NSW and Sydney- Edition 21 - NSW DSRD




	NSW MEDICAL DEVICE COMPANIES PREDICT $34 MILLION IN BUSINESS OUTCOMES FROM MEDICA 2008
	WOLLONGONG RESEARCHERS WORK TOWARDS LONGER LASTING ENERGY
	OVER US $5.7M IN NEW CONTRACTS FOR ATCOR MEDICAL
	ARANA THERAPEUTICS COMPLETES GSK PROJECT AND COMMENCES PHASE II RHEUMATOID ARTHRITIS TRIAL
	APPLICATIONS OPEN FOR $75,000 STEM CELL SCHOLARSHIP
	NSW PARLIAMENT HOSTS ‘KIDS IN THE HOUSE’ TO RAISE AWARENESS ABOUT JUVENILE DIABETES
	BLAME YOUR GENES FOR ILLNESS RESPONSE
	YOUNG RESEARCHER IDENTIFIES BINOCULAR VISION GENE
	RESEARCHERS BRING MIND-CONTROLLED ROBOTIC LIMBS A FEW STEPS CLOSER

BioBusiness Update | NSW and Sydney- Edition 21

> EXPAND ALL ARTICLES

NSW MEDICAL DEVICE COMPANIES PREDICT $34 MILLION IN BUSINESS OUTCOMES FROM MEDICA 2008 NSW medical device companies expect over $34 million in business outcomes over the next year following their participation in a NSW Government trade mission to Germany, Minister for Science and Medical Research Jodi McKay said. Ms McKay said 15 NSW companies attended the world’s biggest medical devices fair, Medica 2008 in Germany, from November 19-22, with the support of the State Government.
Read more		BACK TO TOP \|

WOLLONGONG RESEARCHERS WORK TOWARDS LONGER LASTING ENERGY Researchers at the University of Wollongong’s Intelligent Polymer Research Institute have been chosen as the first funding recipients of a joint technology program between the NSW Government and the South Korean province of Gangwon. Minister for Science and Medical and Research Jodi McKay visit the University of Wollongong on 27 January 2009 to inspect the research facilities and announce the $100,000 joint research grant.
Read more		BACK TO TOP \|

OVER US $5.7M IN NEW CONTRACTS FOR ATCOR MEDICAL AtCor Medical (ASX:ACG), the developer and marketer of the SphygmoCor® system which measures central blood pressures and arterial stiffness non-invasively, recently announced that it has signed new agreements to supply SphygmoCor® systems and clinical trial support services to two leading international pharmaceutical companies. The minimum total value of the contracts is US $860,000 and US $650,000 respectively. These new orders bring the minimum total value of pharmaceutical trial contracts secured by AtCor in the past six months to over US $5.7 million.
Read more		BACK TO TOP \|

ARANA THERAPEUTICS COMPLETES GSK PROJECT AND COMMENCES PHASE II RHEUMATOID ARTHRITIS TRIAL Arana Therapeutics Limited (ASX:AAH) recently announced that it has both: successfully completed optimisation work on a second molecule as part of its ongoing collaboration with GlaxoSmithKline (GSK); and commenced an international multi-centre Phase II dose ranging study in rheumatoid arthritis (RA). Recruitment of the 200 patients is expected to take approximately 12 months with the formal results of the study available in mid-2010.
Read more		BACK TO TOP \|

APPLICATIONS OPEN FOR $75,000 STEM CELL SCHOLARSHIP The NSW Government has established a new scholarship to support cutting-edge stem cell research, Minister for Science and Medical Research Jodi McKay said. Ms McKay said the Dr Paul Brock Stem Cell Scholarship will provide up to $75,000 funding over three years to support PhD research in the emerging field of Induced Pluripotent Stem (iPS) cells.
Read more		BACK TO TOP \|

NSW PARLIAMENT HOSTS ‘KIDS IN THE HOUSE’ TO RAISE AWARENESS ABOUT JUVENILE DIABETES On 25 November, the NSW Parliament hosted 40 children who suffer from juvenile diabetes and their parents to raise public awareness and support for research into the disease, Minister for Science and Medical Research Jodi McKay said. Ms McKay said juvenile diabetes – otherwise known as type 1 diabetes - affects over 8,600 Australian children under the age of 18 with the diagnosis rate growing by three per cent a year.
Read more		BACK TO TOP \|

BLAME YOUR GENES FOR ILLNESS RESPONSE People with certain high-risk gene combinations* are eight times more likely to suffer from a severe and prolonged illness when they have an infection, according to UNSW researchers. This group of people is significantly more likely to have an intense illness during the acute stage of an infection – when fever, aches and pain strike – to signal the start of the body’s immune response.
Read more		BACK TO TOP \|

YOUNG RESEARCHER IDENTIFIES BINOCULAR VISION GENE Dr Catherine Leamey from the School of Medical Sciences at the University of Sydney has been awarded the 2008 Sir Zelman Cowen Universities Fund Prize for Medical Research for her work in identifying the gene that enables binocular vision.
Read more		BACK TO TOP \|

RESEARCHERS BRING MIND-CONTROLLED ROBOTIC LIMBS A FEW STEPS CLOSER Even the most fertile science fiction imagination might not see a link between the behaviour of insects and the development of lifelike robotic limbs, but that is the straightforward mathematical reality of research underway in the University of Technology Sydney (UTS) Faculty of Engineering and Information Technology. PhD student Rami Khushaba knows it takes some explaining, but the analysis of the behaviour of social insects like ants is helping find the best way to tap into the body's electrical signals, so that a robotic prosthetic device can be operated like a flesh and blood limb, just by thinking about it.
Read more		BACK TO TOP \|

WEBSITE | PH: +61 2 9338 6968 | EMAIL
GPO Box 5477, Sydney NSW 2001 AUSTRALIA

Privacy: Any personal information provided to the Department is voluntary and protected by the Privacy and Personal Information Protection Act 1998 (NSW) and the Health Records and Information Privacy Act 2002 (NSW). The Department does not condone the sending of unsolicited commercial electronic messages as defined by the Spam Act 2003 (Cth.). Please refer to our privacy and spam policy for more information and your rights to access and correct the information held.

Disclaimer: This e-newsletter contains information including data, documents and images prepared by the New South Wales Department of State and Regional Development (DSRD). While the information has been formulated with all due care, DSRD does not warrant or represent that the information is complete, accurate or up to date. The information is subject to change without notice.